Longevity & AgingSemaglutide Linked to 15% Lower Fracture Risk in Type 2 Diabetes Patients
A study of over 35,000 adults with type 2 diabetes found that semaglutide users experienced 15% fewer fractures compared to those on other diabetes or obesity medications over roughly 3.5 years. This is notable because diabetes patients already face elevated fracture risk despite normal bone density, and weight loss itself typically accelerates bone loss. Researchers from Stanford presented the findings at ENDO 2026, suggesting semaglutide may offer an unexpected bone-protective benefit beyond blood sugar and weight control. The mechanism is unclear, but GLP-1 receptors are present in bone tissue, and the drug may reduce inflammation and falls risk. Experts say more research is needed to confirm whether this benefit extends to other GLP-1 drugs like tirzepatide.
